{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:03:21Z","timestamp":1780585401971,"version":"3.54.1"},"reference-count":16,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2011,5,25]],"date-time":"2011-05-25T00:00:00Z","timestamp":1306281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ther Apher Dial"],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mineral and bone disorders (MBD), including hypercalcemia and hypophosphatemia, are common complications after renal transplantation; however, the natural course of these disorders has not been well documented, and the pathogenesis of persistent post\u2010transplant MBD still remains elusive. This study was carried out to show the natural history of mineral metabolism in recipients after living\u2010donor kidney transplantation and also to clarify post\u2010transplant risk factors of persistent hypercalcemia and\/or hypophosphatemia at 12\u2003months after transplantation. Living\u2010donor kidney transplant recipients (<jats:italic>N<\/jats:italic>\u2003=\u200334) at Tokyo Women's Medical University were prospectively and consecutively recruited. Parameters of MBD, including intact parathyroid hormone and full\u2010length fibroblast growth factor\u200323, were followed. Serum calcium levels increased until the fourth week post\u2010transplantation, after which it reached a plateau; and serum phosphate decreased substantially at one week post\u2010kidney transplantation, but recovered to the reference level at two months. Fibroblast growth factor\u200323 gradually decreased to comparable levels for renal function, while hyperparathyroidism persisted for 12\u2003months after transplantation. Multivariate linear regression analysis revealed that intact parathyroid hormone was the best correlating factor with both hypercalcemia and persistent hypophosphatemia at 12\u2003months. This study suggests the need for testing of other interventions used for treatment of hyperparathyroidism which may help to offer better management of MBD after kidney transplantation.<\/jats:p>","DOI":"10.1111\/j.1744-9987.2011.00932.x","type":"journal-article","created":{"date-parts":[[2011,5,25]],"date-time":"2011-05-25T14:24:01Z","timestamp":1306333441000},"page":"481-487","source":"Crossref","is-referenced-by-count":21,"title":["Natural History of Mineral and Bone Disorders After Living\u2010Donor Kidney Transplantation: A One\u2010Year Prospective Observational Study"],"prefix":"10.1111","volume":"15","author":[{"given":"Hiroo","family":"Kawarazaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugo","family":"Shibagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Kido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Fuchinoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Teraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,5,25]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1998.00142.x"},{"key":"e_1_2_8_3_2","first-page":"92","article-title":"Hypercalcemic hyperparathyroidism following renal transplantation: differential diagnosis, management. And implications for cell population control in the Parathyroid gland","volume":"8","author":"Parffit A","year":"1982","journal-title":"Miner Electrolyte Metab"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mnh.0000203187.49890.cc"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1997.297"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1982.227"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5001788"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021105"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-197901000-00006"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2004.04.029"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02792.x"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.00938.x"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9610(87)90260-1"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000149698.79739.EF"},{"key":"e_1_2_8_15_2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1681\/ASN.V132551","article-title":"Calcium Metabolism and Skeletal Problems after Transplantation","volume":"13","author":"Torres AV","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(03)00905-3"},{"key":"e_1_2_8_17_2","first-page":"572A","article-title":"Optimum PTH levels before renal transplantation to prevent persistent hyperparathyroidism [abstract]","volume":"9","author":"Torres A","year":"1998","journal-title":"J Am Soc Nephrol"}],"container-title":["Therapeutic Apheresis and Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1744-9987.2011.00932.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1744-9987.2011.00932.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T08:18:19Z","timestamp":1697271499000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1744-9987.2011.00932.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,25]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["10.1111\/j.1744-9987.2011.00932.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1744-9987.2011.00932.x","archive":["Portico"],"relation":{},"ISSN":["1744-9979","1744-9987"],"issn-type":[{"value":"1744-9979","type":"print"},{"value":"1744-9987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,25]]}}}